Table 3.

Cox hazard analysis of clinicopathological and genotypic parameters for PFS in PDA patients who underwent surgical resection (Group 2: n = 85).

		Univariate Analysis
	N	HR	95%CI	p-value
GALNT14		0.632	0.321–1.245	0.185
GG	17
Non-GG	68
Age		1.022	0.611–1.709	0.934
≤65 y	46
>65 y	39
Gender		0.836	0.493–1.416	0.505
Male	56
Female	29
CEA		1.048	0.578–1.901	0.877
≤5 ng/mL	50
>5 ng/mL	24
CA19-9		0.998	0.512–1.947	0.996
≤37 IU/mL	17
>37 IU/mL	56
T-bilirubin		1.08	0.622–1.875	0.784
≤1.4 mg/dL	26
>1.4 mg/dL	50
Tumor location		0.654	0.356–1.203	0.172
Head	67
Body & Tail	17
Tumor size		0.601	0.357–1.011	0.055
≤10 cm3	41
>10 cm3	44
Free margin		0.657	0.371–1.163	0.149
Negative	50
Positive	23
Differentiation		1.262	0.571–2.789	0.565
Well & moderate	71
Poor	13
Tumor invasion		0.914	0.282–2.959	0.881
pT1–3	79
pT4	6
Regional LN		0.644	0.383–1.085	0.099
N0	39
N1-2	46
Metastasis		-	-	-
M0	85
M1	0
Peritoneal invasion		-	-	-
No	85
Yes	0
Vascular invasion		0.959	0.518–1.776	0.895
No	66
Yes	19
Lymphatic invasion		0.648	0.378–1.108	0.113
No	34
Yes	51
Perineural invasion		0.93	0.517–1.673	0.81
No	22
Yes	63
Adjuvant C/T		1.323	0.789–2.219	0.289
No	55
Yes	30

Abbreviations: PFS = progression-free survival, PDA = pancreatic ductal adenocarcinoma, GALNT14 = N-acetylgalactosaminyltransferase14, y = year, CEA = carcinoembryonic antigen, CA 19-9 = carbohydrate antigen 19-9, T-bilirubin = total bilirubin, LN = lymph node, C/T = chemotherapy, HR = hazard ratio, and CI = confidence interval.